Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

08 nov. 2012 16h30 HE | Source: Momenta Pharmaceuticals

Momenta Pharmaceuticals to Webcast Presentations at Two Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 8, 2012 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
07 nov. 2012 08h00 HE | Source: Momenta Pharmaceuticals

Momenta Pharmaceuticals Reports Third Quarter 2012 Financial Results

CAMBRIDGE, Mass., Nov. 7, 2012 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
18 oct. 2012 16h48 HE | Source: Momenta Pharmaceuticals

Momenta Pharmaceuticals Announces Date of Third Quarter 2012 Financial Results Conference Call

CAMBRIDGE, Mass., Oct. 18, 2012 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will...
30 août 2012 17h00 HE | Source: Momenta Pharmaceuticals

Momenta Pharmaceuticals to Webcast Presentations at Two Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 30, 2012 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
08 août 2012 16h01 HE | Source: Momenta Pharmaceuticals

Momenta to Present at the Canaccord Genuity 32nd Annual Growth Conference

CAMBRIDGE, Mass., Aug. 8, 2012 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
03 août 2012 16h56 HE | Source: Momenta Pharmaceuticals

Momenta Pharmaceuticals Acknowledges Federal Circuit Opinion Supporting Order Issued January 26, 2012 in Ongoing Suit Against Amphastar Pharmaceuticals and Watson Pharmaceuticals

CAMBRIDGE, Mass., Aug. 3, 2012 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
02 août 2012 08h00 HE | Source: Momenta Pharmaceuticals

Momenta Pharmaceuticals Reports Second Quarter 2012 Financial Results

CAMBRIDGE, Mass., Aug. 2, 2012 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
16 juil. 2012 08h00 HE | Source: Momenta Pharmaceuticals

Momenta Pharmaceuticals Announces Date of Second Quarter 2012 Financial Results Conference Call

CAMBRIDGE, Mass., July 16, 2012 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will...
02 juil. 2012 08h30 HE | Source: Momenta Pharmaceuticals

First Patient Dosed With M402 in Phase 1/2 Clinical Trial in Metastatic Pancreatic Cancer

CAMBRIDGE, Mass., July 2, 2012 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
22 juin 2012 21h02 HE | Source: Momenta Pharmaceuticals

Momenta Pharmaceuticals Announces Decision in Teva Patent Litigation

CAMBRIDGE, Mass., June 22, 2012 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...

Page précédente

Page suivante